Paul K. Wotton

Paul K. Wotton (board member) discloses dealings in 3 companies, chiefly Antares Pharma, Inc., Vericel Corp and Ocata Therapeutics, Inc. Over a trading history stretching from 10 May 2007 to 29 April 2026, the count stands at 76 filings.

On the open market, the record shows 4 purchases worth €27k and 23 sales worth €3.3M. Sales outweigh purchases by €3.2M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The rest of the record consists of 21 share grants and 26 option exercises.

A typical purchase (the median) is worth €6,274.

The latest filing, published on 1 May 2026, reports an option exercise in Vericel Corp. The last insider purchase was made public on 24 August 2010, 5,905 days ago. Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.